EtiraRX, Inc.

Biotechnology · DALLAS, TX

BiotechnologySEC Form D

EtiraRX, Inc. filed a Form D with the U.S. Securities and Exchange Commission on May 14, 2026, reporting $2,277,533 raised toward a $3,000,003 offering.

Incorporated in Delaware and based in DALLAS, TX, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that EtiraRX, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Russell HaywardExecutive Officer · Director
  • Ganesh RajExecutive Officer · Director
  • Justin StebbingDirector
  • Annalisa JenkinsDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
$1.6MRaised

Biolexis Therapeutics Inc.

BiotechnologyLEHI, UT
EtiraRX, Inc. raised $2.3M — SEC Form D